# Novo Nordisk to invest $4.1B in second fill-finish facility in Clayton, North Carolina

Novo Nordisk announced plans to invest $4.1 billion to build a second fill and finishing manufacturing facility in Clayton, North Carolina, adding 1.4 million square feet and 1,000 jobs. The facility will produce injectable treatments for obesity and chronic diseases.

- Type: Expansion
- Announced: 2024-06-24
- Where: Clayton, North Carolina, United States
- Value: $4.10B
- Jobs: 1,000
- Starts operating: 2027
- Status: announced
- Capacity: 1.4 million square feet
- Products: injectable treatments for obesity and chronic diseases, Wegovy, Ozempic
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novo Nordisk](https://endata.com/companies/17868.md)
- [BE&K Building Group](https://endata.com/companies/68155.md) (partner)

## Sources

- [globenewswire.com](https://www.globenewswire.com/news-release/2024/06/24/2903283/0/en/novo-nordisk-announces-4-1-billion-usd-investment-to-expand-us-manufacturing-capacity.html), 2024-06-24: "Novo Nordisk today announced plans to invest 4.1 billion US dollars to build a second fill and finishing manufacturing facility in Clayton, North Carolina, and grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases."
- [reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-maker-novo-nordisk-spend-41-bln-boost-us-manufacturing-2024-06-24/), 2024-06-24: "Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on Monday."
- [digital.enr.com](https://digital.enr.com/articles/expanding-pharmaceutical-production), 2024-07-13: "Clayton was the first manufacturing site for Novo Nordisk in the U.S., and this new, large-scale investment here confirms the continued importance of our production facilities in North Carolina."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.